June 8 - BioMarin’s valoctocogene roxaparvovec Hemophilia A Clinical Development Program

June 1 - Kogenate FS Discontinuation

May 17 - Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia

May 10 - Women's health articles from HEMAWARE, the bleeding disorders magazine produced by NHF.

April 26 - Roctavian’s Effectiveness Tied to Molecules that Aid FVIII Production

March 23 - Low Red Blood Cells, Clotting Factor Levels Tied to Surgery Bleeding Risk

March 8 - Researchers secure $12 million grant to develop improved therapies for hemophilia

March 7 - The CDC recently released updated statistics about hemophilia characteristics among women and girls receiving care at specialized Hemophilia Treatment Centers (HTCs) in the United States.

February 7 - Update regarding BioMarin’s ongoing Phase 3 hemophilia A gene therapy study.

January 24 - Preventive Esperoct Plus Surgery Reduces Joint Bleeds, Aids Mobility

November 1 – Performing serial MRIs in young patients with hemophilia may spot early joint damage

October 21 - CDC director weighs in on trick-or-treating amid the pandemic

October 18- Reverse Vaccination’ May Help Prevent Immune Response 

September 29 - Treatment prevents development of antibodies against drugs for hemophilia A and Pompe disease.

September 14 - SerpinPC, for Hemophilia A and B, Safely Prevents Bleeds in Phase 2a Trial

August 30 - The New Frontier of Hemophilia Treatment - Specialty Pharmacy Continuum

August 23 - Continuing Prophylaxis into Young Adulthood Improves Outcomes for Patients with Hemophilia

August 12 - National Vaccination Awareness Month: Chronic Conditions & Immunizations – BioMatrix Abstract

August 1: Manual Therapy Improves Joint Health in Hemophilia Patients

July 21:  Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

 

 

Skip to content